Impact News +++ Vuzix shares soar on virtual healthcare collaboration with Hippo Technologies (SeekingAlpha) +++ VUZIX Aktie +4,76%

BIOCRYST Aktie

 >BIOCRYST Aktienkurs 
7.65 EUR    +2.3%    (Tradegate)
Ask: 7.69 EUR / 676 Stück
Bid: 7.57 EUR / 687 Stück
Tagesumsatz: 7235 Stück
Realtime Kurs von 8 bis 22 Uhr!
>BIOCRYST Performance
1 Woche: +15,6%
1 Monat: +8,0%
3 Monate: +153,8%
6 Monate: +70,9%
1 Jahr: +203,4%
laufendes Jahr: +33,0%
>BIOCRYST Aktie
Name:  BIOCRYST PHARMAC. DL-,01
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US09058V1035 / 896047
Symbol/ Ticker:  BO1 (Frankfurt) / BCRX (NASDAQ)
Kürzel:  FRA:BO1, BO1.F, BO1:GR, NASDAQ:BCRX
Index:  -
Webseite:  http://www.biocryst.com/
Marktkapitalisierung:  1110 Mio. EUR
Umsatz:  44.26 Mio. EUR
EBITDA:  -100.64 Mio. EUR
Gewinn je Aktie:  -0.662 EUR
Schulden:  66.8 Mio. EUR
Liquide Mittel:  118.51 Mio. EUR
Umsatz-/ Gewinnwachstum:  243.80% / -
KGV/ KGV lG:  - / -
KUV/ KBV/ PEG:  22.74 / 40.96 / -
Gewinnm./ Eigenkapitalr.:  -233.45% / -
Dividende je Aktie:  -
Dividendenrendite/ -schätzung:  - / -
Insiderhandel:  -
Suchwörter:  BIOCRYST
Letzte Datenerhebung:  20.01.21
>BIOCRYST Eigentümer
Aktien: 176.57 Mio. St.
f.h. Aktien: 162.25 Mio. St.
Insider Eigner: 0.85%
Instit. Eigner: 73.95%
Leerverk. Aktien: 18.84%
>BIOCRYST Peer Group

 
07.01.21 - 13:09
 BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire EN)
 
RESEARCH TRIANGLE PARK, N.C., Jan. 07, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted 10 newly-hired employees inducement options to ...
06.01.21 - 13:03
 BioCryst to Present at 39th Annual J.P. Morgan Healthcare Conference (GlobeNewswire EN)
 
RESEARCH TRIANGLE PARK, N.C., Jan. 06, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the 39th Annual J.P. Morgan Healthcare Conference, which is being conducted as a virtual ...
23.12.20 - 17:18
 BioCryst (BCRX) Provides Updates on Galidesivir, Shares Fall (Zacks)
 
BioCryst (BCRX) will discontinue the study on its pipeline candidate, galidesivir, for treating patients with the novel coronavirus disease (COVID-19)....
23.12.20 - 08:45
 CYCC Gets $7Mln Strategic Investment, SUPN Abuzz, SNGX Plunges On Oral Mucositis Trial Data (RTTNews)
 
Today's Daily Dose brings you news about BioCryst's update on its investigational broad-spectrum antiviral Galidesivir in the treatment of COVID-19, a $7 million strategic investment by Acorn Bioventures in Cyclacel Pharma, and Supernus' phase III...
22.12.20 - 18:36
 Why BioCryst, VistaGen And Teladoc Are Moving Today (Benzinga)
 
VistaGen Therapeutics (NASDAQ: VTGN) shares are trading higher after Maxim raised its price target on the stock from $3 to $5. read more...
22.12.20 - 17:54
 Why BioCryst Pharmaceuticals Stock Is Sinking Today (Fool)
 
Investors were disappointed by the biotech's COVID-19 clinical trial results....
22.12.20 - 14:06
 BioCryst to stop testing galidesivir in COVID-19 patients (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
22.12.20 - 13:03
 BioCryst Provides Update on Galidesivir Program (GlobeNewswire EN)
 
RESEARCH TRIANGLE PARK, N.C., Dec. 22, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that data from part 1 of a clinical trial of its broad-spectrum antiviral, galidesivir, showed that galidesivir was safe an...
21.12.20 - 20:24
 BioCryst down despite positive early-stage study data with BCX9250 in bone/tissue disorder (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
21.12.20 - 16:33
 The Zacks Analyst Blog Highlights: Quidel, Halozyme Therapeutics, Teladoc Health, Acceleron Pharma and BioCryst Pharmaceuticals (Zacks)
 
The Zacks Analyst Blog Highlights: Quidel, Halozyme Therapeutics, Teladoc Health, Acceleron Pharma and BioCryst Pharmaceuticals...
21.12.20 - 13:06
 BioCryst Announces Positive Phase 1 Results with BCX9250, an Oral ALK-2 Inhibitor for Treatment of Fibrodysplasia Ossificans Progressiva (GlobeNewswire EN)
 
RESEARCH TRIANGLE PARK, N.C., Dec. 21, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that in a Phase 1 clinical trial with BCX9250, an oral activin receptor-like kinase-2 (ALK-2) inhibitor discovered and dev...
18.12.20 - 06:02
 Insiderhandel: President & CEO verkauft Aktien von BioCryst im Wert von 1.117.193 $ (Insiderkauf)
 
Stonehouse, Jon P. - Vorstand - Tag der Transaktion: 2020-12-15...
16.12.20 - 13:24
 BioCryst′s Orladeyo now available in U.S. (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
16.12.20 - 13:03
 BioCryst Announces U.S. Availability of ORLADEYO™ (berotralstat) for the Treatment of Hereditary Angioedema (GlobeNewswire EN)
 
—Direct to patient shipments of the first oral, once-daily prophylactic treatment underway through Optime Care— ...
16.12.20 - 08:01
 Insiderhandel: Senior VP, Chief Legal Officer verkauft Aktien von BioCryst im Wert von 109.378 $ (Insiderkauf)
 
Barnes, Alane P. - Vorstand - Tag der Transaktion: 2020-12-11...
14.12.20 - 15:36
 Thinking about buying stock in Inseego Corp, Ampio Pharmaceuticals, Marathon Patent Group, Regulus Therapeutics, or BioCryst Pharmaceuticals? (PR Newswire)
 
NEW YORK , Dec. 14, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for INSG, AMPE, MARA, RGLS, and BCRX....
>Zitat des Tages: Die Jugend ist ein Rosenkranz, das Alter ist ein Dornenkranz. - Talmud
Partner:    >Tradegate Börse | >TraderFox Handelssignale | >Heibel-Ticker Börsenbrief | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf Twitter | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!